While tyrosine-kinase inhibitors (TKIs) [110] and anti-VEGF(R-2) antibodies with [111,112] or without anti-PD-(L)1 [113,114] treatments had proven limited efficacy in an unselected population with refractory CCA, novel studies are evaluating the concomitant dual blockade of VEGF/PD-1 (NCT06529718) and VEGF-A/DLL4 (NCT04492033, NCT05506943) with bispecific antibodies. The gene discussed is VEGFA; the disease is cholangiocarcinoma.